Advances In Multiple Sclerosis Research

A good way to understand this area of interest is to read the following paragraphs you have come to the right place.

Multiple sclerosis is a disease that attacks the brain and spinal cord and can lead to damage in the central nervous system. It is believed that there are three million people with multiple sclerosis, worldwide. Drug cocktails are used to control the debilitating symptoms of MS, but a cure is still to come. In this article, we'll examine the latest developments in MS research and the challenges that scientists still face.

Many significant developments have been made in neuroscience and multiple sclerosis research during the last several years. Eli Lilly and Co. and BioMS Medical Corp. have completed the development of an experimental drug called MBP9289. The two companies say MBP9289 has shown promise in delaying progression and worsening of multiple sclerosis. The drug is in two Phase 3 clinical trials and one Phase 2 trial, and is still years away from the market.

MRI multiple sclerosis monitoring is proving to be invaluable. Scientists are now able to see and follow the development of MS lesions in the brain and spinal cord. This is a tremendous aid in the assessment of new therapies and can speed up the process of evaluating new treatments. There are a number of treatments under investigation that may curtail attacks or improve the function of damaged nerve fibers. Over a dozen clinical trials testing potential therapies are underway, and additional new treatments are being devised and tested in animal models.

In multiple sclerosis news, the bio pharmaceutical company MediciNova Inc. has announced data from a double-blind analysis of the first year of treatment from its two-year Phase II clinical trial of MN-166 in multiple sclerosis. The second year of the Phase II clinical trial is on-going with results expected in April 2008.

The analysis showed that MN-166 decreased the formation of brain lesions that are believed to indicate the death of nerves in the brain on MRI in MS patients. Treatment with a 30 mg/day dosing regimen of MN-166 showed a trend toward reduced risk of new lesion evolution to persistent black holes when compared to a placebo. This means that when diagnosed early, patients can stave off the symptoms of MS.

We've come a long way, but multiple sclerosis research still has a long road to travel. The role of genetic risk factors, and how they can be modified, must be more clearly defined. Environmental triggers, such as viruses or toxins, need to be investigated further. Knowledge of these aspects of the disease will enable scientists to develop new methods for halting, reversing or repairing the destruction of myelin that causes the symptoms of MS. Scientists are still diligently pursuing aggressive research, so there is a hope of one day finding a cure for multiple sclerosis.

This is just one article there are many more why not browse through a few more!

Technorati Tags: Multiple Sclerosis, Advances In Multiple Sclerosis Research, Multiple Sclerosis Research

• Multiple Sclerosis
• The Facts About Multiple Sclerosis
• Acquired Pendular Nystagmus And Multiple Sclerosis
• Alternative Help For Multiple Sclerosis
• Care For Multiple Sclerosis
• Early Symptoms Of Multiple Sclerosis
• Glyconutrients And Multiple Sclerosis
• Historical Significance Of Multiple Sclerosis
• Tips For Living With Multiple Sclerosis
• Understanding Multiple Sclerosis
• Multiple Sclerosis Diet
• Living With Multiple Sclerosis Pain
• What Multiple Sclerosis Patients Need To Know
• Multiple Sclerosis Questions
• Advances In Multiple Sclerosis Research
• Multiple Sclerosis Signs Symptoms
• Multiple Sclerosis Symptoms
• The Facts About Multiple Sclerosis Treatment
• Multiple Sclerosis Treatment Options
• Multiple Sclerosis Support Group
• Social Bookmark This
• 
• 
• 
• 
• 
• 
• Sitemap
• Multiple Sclerosis Partners